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Abstract
The hallmarks of cancer currently define the molecular mechanisms responsible for 
conferring specific tumor phenotypes. Recently, these characteristics were also connected to 
the status of the secretory pathway, thereby linking the functionality of this cellular machinery 
to the acquisition of cancer cell features. The secretory pathway ensures the biogenesis of 
proteins that are membrane-bound or secreted into the extracellular milieu and can control its 
own homeostasis through an adaptive signaling pathway named the Unfolded Protein 
Response (UPR). In the present review, we discuss the specific features of the UPR in various 
tumor types and the impact of the selective activation of this pathway on cell transformation, 
tumor development and aggressiveness. 
Keywords: endoplasmic reticulum, cancer, stress, tumor, EMT
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Introduction
Tumor phenotypes including development and aggressiveness features can dramatically vary 
depending on the origin of tumor cells and context. The hallmarks of cancer defined by 
Hanahan and Weinberg [1] have helped to define these characteristics, which were also 
connected to the status of the secretory pathway (SP) [2, 3]. As a consequence this essential 
cellular component has taken significant importance in the acquisition of cancer cell features. 
The SP ensures the biogenesis of proteins that are membrane-bound or secreted into the 
extracellular milieu. It is well accepted that approximately one-third of the polypeptides 
synthesized by a cell, enter the endoplasmic reticulum (ER), the first compartment of the SP 
[2, 3]. However, the quantity of proteins entering the secretory pathway fluctuates, depending 
on the cell physiology, function and specific microenvironment. For instance, the synthesis of 
antibodies, extracellular matrix proteins, membrane receptors or secretory cyto/chemokines is 
cell type specific and can impact the workload of the secretory machinery. Moreover, cell 
migration, differentiation or proliferation features can also create the demand for a higher 
need for protein secretion. Protein secretion fluctuations affect cell homeostasis, particularly 
cell amino acid, lipid and sugar metabolism and energy consumption. As such, a strong and 
reliable adaptive system is central for the cell to cope with the increased demand for protein 
folding in the ER. This adaptive system is named the Unfolded Protein Response (UPR). In 
this review, we provide specific examples illustrating how the diversification of UPR signals 
in many human cell types, particularly in secretory cells, could impact typical cancer 
initiation, tumor development and cancer cell aggressiveness.
The UPR transmits stress signals from the ER lumen to the rest of the cell by three 
different proteins called PERK, ATF6 and IRE1. PERK (PKR-like endoplasmic reticulum 
kinase) is a transmembrane protein with a specific kinase activity in its cytosolic domain. Its 
main substrate is the translation initiation factor eIF2?????????????????????????????????????????
decrease in translation as well as a preferential translation of key proteins such as CHOP and 
GADD34, two factors directly involved in the cellular decisions of life or death. The 
transmembrane protein ATF6 (Activating Transcription Factor 6) is an ER transcription 
factor. Under stress conditions, ATF6 is exported to the Golgi apparatus, cleaved and released 
from its membrane attachment by the proteases S1P and S2P, to play its role as nuclear 
transcriptional activator. Finally, IRE1 (Inositol Requiring Enzyme 1), an ER resident type 1 
transmembrane protein, has two enzymatic activities in its cytosolic domain: a 
serine/threonine kinase and an endoribonuclease activity. The endoribonuclease activity itself 
has two distinct molecular functions: i) it participates in the unconventional splicing of the 
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XBP1 transcription factor mRNA [4]; ii) it degrades the mRNA of several secreted proteins, a 
process called RIDD (Regulated IRE1-Dependent Decay of RNA) [5]. The integration of 
signals from these three molecular pathways leads to a general transcription and translation 
reorientation, in favor of cell survival. Among the cellular processes regulated, the antioxidant 
capacity is increased, protein synthesis is decreased and the expression of ER chaperones/ER 
quality control proteins involved in protein folding (BiP, GRP94, CRT, PDIs) and in 
misfolded protein degradation is enhanced [6-8]. Finally, if ER homeostasis is not restored, 
ER stress can trigger apoptosis [9 , 10] (Figure 1).
It is well established that differentiated cells such as neurons, blood cells, panc????????-
cells, hepatocytes, all require a dedicated secretory pathway with appropriate specialized 
regulations [11]. In accordance with this, an increasing number of studies have shown a 
dependency of specific UPR components for the differentiation of particular cell types. For 
instance, the IRE1-????? ??????? ??? ????????? ???? ???? ???????????????? ??? ??????????? ?? ???????
plasma cells, or adipocytes [12 , 13 , 14 , 15 , 16] and disturbance of the PERK-ATF4 
pathway triggers defects in oligodendrocytes, pancreatic and skeletal functions [17 , 18 , 19 , 
20 , 21].
A. The “secretory switch” in transformed cells
Most cancers have to cope with increasing fluxes of proteins through their secretory pathway. 
This high secretory protein demand is caused by different hallmarks of cancer [2] and 
comprises all the processes that increase gene expression, in an unspecific manner, such as 
aneuploidy or the universal amplifier of transcription, MYC [22 , 23]. Hence, it is not 
surprising that aneuploidy was found to be associated to hypersensitivity to conditions 
interfering with protein synthesis and protein folding in yeast [24] and in human cancer cells 
[25], and that MYC transformation requires a reliable secretory pathway to mediate its 
oncogenic potential [26]. Moreover, cell transformation can result in an increase in 
proliferation and metabolic demand, thereby leading to nutrient (i.e. glucose, amino acids) 
depletion and subsequent ER stress [27]. This means that during the cell transformation 
process, a “secretory switch” occurs and provides the transformed cells with novel secretory 
properties, which will in turn impact on cell homeostasis and interaction with the stroma.
What are the consequences of the “secretory switch” and associated ER stress on 
tumor-stroma interactions? First, it can lead to microenvironment architecture destabilisation 
by remodelling of the extracellular matrix (ECM) through changes in ECM components 
abundance or matrix metalloproteases (MMPs) expression, and consequently, to an increase 
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in cancer dissemination and invasion [28 , 29]. Second, by modulating messenger (i.e. 
chemokines, cytokines) or contact/adhesion protein abundance (i.e. membrane receptors, 
integrins), the “secrotory switch” and associated ER stress can trigger cancer cell 
proliferation, migration or tumor angiogenesis. Third, it can lead to remodelling of the 
immune response and ER stress transmission in the tumor microenvironment [30, 31]. Fourth, 
it can modulate tumor immunogenicity by stimulating surface exposure of ER chaperones 
such as CRT [2, 32 , 33 ] (Figure 2). 
A.1. UPR involvement in gastrointestinal cancer initiation
The UPR is a central pathway for intestinal functions and differentiation, and the human 
gastrointestinal tract represents an interesting example of UPR specialization. This is well 
illustrated by the immunostaining of UPR components in the normal intestine, which showed 
that UPR activation occurs in a heterogeneous manner in intestinal cell populations. Indeed, 
GRP78 abundance appeared high in transit amplifying cells (TA), low in intestinal stem cells 
(ISC) and heterogenous in Paneth cells [34]. This suggests that the UPR could be induced 
with intestinal cell differentiation or could represent a pathway driving differentiation. One 
????????????????????????????????????????????????????????????????????????????????????????????????
sufficient to trigger the loss of ISC stemness [34]. Considering that ISCs are thought to 
represent the cells of origin for most colorectal cancers (CRCs) [35], this suggests that ER 
stress could have central implication for cancer initiation in the gastrointestinal tract.
Apart from the PERK/eIF2???????????????????????????????????????????????????????????????????
the IRE1 branch. Indeed, the gastrointestinal tract is the main tissue where the two IRE1 
??????????????????????????????????????????????????????????????????[36]. Although the functions 
??????????????????????????????????????????????????????????????????????????????????????????
production in goblet cells [37] and in resistance to chemically induced colitis [36]. Moreover, 
XBP1 deficiency or expression of XBP1 variants was associated with Crohn’s disease and 
ulcerative colitis [38]. Interestingly, IRE1???????????????????????????????? ????????????????
increased ER stress and inflammation of the intestine. A more recent report described the 
association between inflammatory bowel disease and tumorigenesis upon targeted deletion of 
XBP1 in the intestine [39]. In this model, XBP1 loss in epithelial cells results in an increase in 
colorectal cancer and colitis-associated cancer. This effect was attributed to an increase in ISC 
and TA cells, and a dysfunction of Paneth cells. ISC hyperproliferation was linked to 
increased WNT11 expression in Paneth cells and TA cells hyperproliferation to the activation 
of an ER stress-dependent interleukin/STAT3 pathway. Interestingly, in this study, a 
transgenic mouse model presenting a d??????????????????????????????????????????????????
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present ISC hyperproliferation observed in XBP1 deficient mice. Although one can ask the 
????????? ??? ???? ?????? ??? ??????? ??????????? ??? ???? ????? ???? ??????????? ?????? ??? ??????
processes, the authors proposed ?????????????????????????????????????????????????????????????
expansion, in an XBP1-independent manner, which might leave room for an instrumental role 
????????? ??? ???????????????????????? ?????????? ?????? ????????? ????? ???? ?????-???????-???
pathway was central for ER stress-induced inflammation [40]. Parallel to these mechanisms, 
??????????????????????????????????????????????????????????????????????????????????????????
and ER stress-induced intestinal inflammation. This was proposed as an explanation for the 
identification of mutations in autophagy components as risk factors in Crohn’s disease [40]. 
Finally, adding to the role of the UPR in intestinal epithelium, XBP1 was also identified as a 
susceptibility locus associated with oesophagus squamous cell carcinoma [41] and ER stress 
was shown to induce epithelial differentiation in precursor cells in the oesophagus [42] and 
also may be linked to Barett’s syndrome [43].
These studies provide good examples of i) how the UPR can fine-tune the entire 
functions and differentiation of the gastrointestinal epithelia by integrating information from 
the microenvironment and ii) how deregulation of this molecular pathway (XBP1 deletion) 
can impact inflammatory bowel disease and gastrointestinal cancer initiation. 
A.2. UPR in blood cancers: transformation, progression and drug resistance
Blood associated cancers represent interesting models in which UPR signals might determine 
tumor phenotypes. First of all, the expression and activity of UPR components including BiP, 
IRE1??????????? ????????????? ????????? ???? ???????????????????????????????????? ????????????
cells and are found overexpressed in plasma cell-derived multiple myeloma (MM). MM 
evolves from a highly prevalent premalignant condition termed monoclonal gammopathy of 
undetermined significance (MGUS). A MGUS/MM phenotype was recently reported in 
transgenic mice with Em-directed expression of the XBP1 spliced isoform (XBP1s). This was 
corroborated with the aberrant expression of known human MM dysregulated genes and thus 
implicates XBP1s dysregulation in MM pathogenesis [44]. Interestingly, Cre-mediated and 
inducible deletion of BiP, BLIMP1 or XBP1 consistently induces cellular stresses and cell 
death in normal pre-B cells and in pre-B-cell acute lymphoblastic leukemia (ALL) driven by 
BCR-ABL and NRAS [45]. Moreover, two ALL clinical trials revealed that high XBP1s 
levels at the time of diagnosis predicted poor outcome. As such, pharmacological inhibition of 
IRE1-induced selective cell death in patient-derived pre-B ALL cells and significantly 
prolonged survival of transplanted mice. As a consequence, pre-B ALL cells appeared 
uniquely vulnerable to ER stress [45]. In a recent study, the Hypoxia Inducible Factor (HIF)-
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????????????????????? ????????????????????????????????????????????????????????????????????
and in the maintenance of hematopoietic stem and progenitor cells (HSPCs). The mechanism 
controling maintenance of HSPCs also involved ER stress signaling as HIF-??-deficient 
HSPCs displayed increased production of reactive oxygen species (ROS), which subsequently 
triggered apoptosis by activation of the UPR [46]. Hence these results might suggest an 
instrumental role of the UPR in HSPC differentiation program and in maintenance of the 
AML phenotype. In another model of blood-derived cancer, Chronic Myeloid Leukemia 
(CML), apoptotic death triggered by the BCR-ABL inhibitor, Imatinib, is activated 
downstream of ER stress [47]. Moreover, Imatinib resistance in CML K562 cells was 
bypassed when preventing the activation of the ATF6 arm of the UPR, thus demonstrating the 
strong interconnection of these pathways in acquisition of tumor cell phenotypes [48].
B. UPR and EMT: an intricate relationship
Epithelial to Mesenchymal Transition (EMT) enables carcinoma cells to acquire key 
malignant traits such as migratory and invasion properties, induces stem cell properties and 
drug resistance [49 , 50 , 51]. Hallmarks of this transition are repression of epithelial markers, 
up-regulation of mesenchymal markers and changes in morphology. During EMT, the 
phenotype of carcinoma cells is largely modified, for example the loss of epithelial polarity 
and zonula adherens mediated by the down-regulation of E-cadherin. E-cadherin is a cell 
adhesion protein and its cytosolic domain is associated at the membrane of the cell to ?-
catenin, which is a major player of the canonical WNT pathway [52]. Through EMT, 
diminution of E-cadherin leads to the release of ?-catenin, resulting in its nuclear 
translocation. In the nucleus, ?-catenin associates with transcription factors of the TCF/LEF 
family to regulate transcription of genes involved in EMT, migration and invasion. Activation 
of the UPR has been involved in a growing number of cancers [53], but the link between UPR 
and EMT has been studied recently in breast cancers. Indeed, recent reports show an 
interrelationship between UPR signals and EMT, in a context specific manner [54 , 55 , 56].
B.1. Activation of the UPR is instrumental for EMT induction
This phenomenon was first reported in thyroid cells, in which tunicamycin or thapsigargin 
triggered signaling by the proto-oncogene tyrosine kinase SRC, caused dedifferentiation 
through the down-regulation of thyroid specific genes and induced an EMT-like phenotype. 
This included the change in the organization of the polarized epithelial monolayer, the 
formation of actin stress fibers, the loss of trans-epithelial resistance, the down-regulation of 
E-cadherin and the up-regulation of mesenchymal markers such as vimentin, ?-smooth actin, 
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?1I collagen and SNAI1/SIP1. Moreover the use of PP2, a SRC kinase inhibitor prevented 
dedifferentiation and EMT, thus confirming the involvement of the SRC pathway [54].
Moreover, the UPR (induced by tunicamycin or overexpression of a variant protein) in 
alveolar epithelial cells was shown to trigger the SRC and ?-catenin pathways [57]. Again, the 
use of PP2 also blocked the EMT and maintained the epithelial phenotype. Notably no 
increase in TGF-?1, an important mediator of EMT, was observed in this report. Interestingly, 
in renal proximal tubular epithelial cells, thapsigargin induced an EMT whereas tunicamycin 
did not [58]. ER stressors that alter calcium fluxes between the ER lumen and the cytosol such 
as thapsigargin lead to an increased expression of TDAG51 and TGF-?1. TDAG51 interacts 
with the cytoskeleton and induces shape changes as well as the activation of WNT signaling 
thereby leading to EMT. As such, overexpression of TDAG51 alone was able to induce an 
EMT phenotype in HK-2 cells. The serine/cysteine protease inhibitor SCCA1 is deregulated 
in many cancers associated with poor differentiation and aggressiveness. In mammary 
epithelial cells (MCF10A), overexpression of SCCA1 induces chronic UPR. This non-lethal 
chronic UPR activates NF-?B that leads to IL-6 production, resulting in EMT-like phenotypes 
[59]. It has been recently reported that IL-6 signaling plays a critical role in driving EMT 
through cell autonomous inflammation [60 , 61]. In light of these reports, activation of UPR 
can lead to EMT trough several mechanisms including IL-6, SRC and/or WNT signaling, but 
how the UPR is triggered, either through alteration of calcium concentrations or increase of 
improperly folded proteins, might also determine the biological outcome. Thus, one might 
hypothesize that ER stressed cells enter dedifferentiation/EMT to change their phenotypes and 
consequently lower ER stress [57]. 
B.2. EMT induces activation of the UPR in colorectal and breast carcinoma
Cells subjected to EMT are also known to display an important secretory phenotype notably 
by changes in ECM protein secretion [62 , 63]. This could represent a cause for ER stress and 
UPR activation. In colorectal carcinoma cells (SW480, HCT116), stabilization of HIF1??
through CoCl2–mediated inhibition of proline hydroxylase, or serum starvation, induces EMT 
and the subsequent activation of the UPR [64]. This mechanism is in part dependent upon 
ZEB-1, which is the main factor for EMT in colorectal carcinoma cells and a transcriptional 
repressor for E-cadherin [52 , 65 , 66]. In mammary epithelial cells, EMT induction by 
TWIST overexpression correlates with PERK constitutive activation [55]. Other branches of 
the UPR (i.e. IRE1????????????????????????????????????????????????????????????????????????????
PERK activity attenuated cells‘ ability to migrate and to form tumor spheres, thereby 
indicating that PERK might be involved in EMT-dependent cell malignancy. In addition, 
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PERK signaling in EMT dedifferentiated cells leads to constitutive activation of NRF2, a 
master regulator of cellular response to oxidative damage, causing these cells to become 
chemoresistant through expression of antioxidant enzymes and drug efflux pumps [67, 68 , 
69]. These results might therefore explain the correlation observed between PERK activation 
status and highly aggressive and poorly differentiated breast cancer tumors. It is noteworthy 
that in tubular epithelial cells both EMT and UPR are activated simultaneously through 
reactive oxygen species (ROS) and SRC kinase-dependent pathways [70].
C. Targeting UPR as a novel approach to treat EMT chemoresistant cells
As there is a hierarchical relationship between UPR and EMT it could allow the development 
of new treatment strategies. Indeed, in diseases where EMT is induced by UPR e.g. lung 
fibrosis, chronic kidney disease or breast cancer [57 , 58, 59 ] targeting the UPR or the 
downstream activated pathways (e.g. SRC, WNT) with inhibitors might be an efficient way to 
prevent cells from undergoing EMT. In vitro, results were already observed with PP2 
targeting the SRC kinase and preventing both PC C13 cells (thyroid cells) and alveolar 
epithelial cells from undergoing an EMT [54, 57 ]. Currently, ER stress drugs are only used to 
treat multiple myeloma patients [71], however because EMT is associated with 
chemoresistance and invasiveness [49 , 50 , 51], there is a critical need to develop new 
approaches, therefore it might be very attractive to exploit the ER stress-sensitivity exhibited 
by cells subjected to EMT [64]. Indeed it was shown that in breast cancer cells several ER 
stressors such as tunicamycin, thapsigargin, DTT and A23187 render EMT undergoing cells 
more sensitive to cell death (up to 25 fold for thapsigargin). These treatment could even 
selectively eliminated EMT undergoing cells when co-cultivated with normal cells [55]. Also 
targeting the PERK pathway that is constitutively active in breast cancer [56 , 72] could also 
be a promising option. Indeed PERK is required for the cells to secrete new extracellular 
matrix and to enable EMT undergoing cells to invade, metastasize and form tumor spheres. 
PERK is also responsible for the constitutive activation of NRF2 in EMT undergoing human 
breast epithelial cells, causing cells to become MDR. Inhibition of PERK caused the 
decreased expression of 58 of the 142 NRF2 target genes and sensitized cells to 
chemotherapy. Together these observations suggest that targeting the UPR and its 
downstream effectors could be a key therapeutic strategy in the treatment of drug-resistant 
cancer cells.
C.1. UPR control of glioblastoma phenotypes
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Glioblastoma (GBM) is the most common primary brain tumor in humans and remains 
incurable [73]. Despite the therapeutic efforts made in recent years, mortality is still close to 
100% at 5 years. Different factors are involved in GBM aggressiveness, among which 
angiogenesis and tumor cell invasion/infiltration are critical [74 , 75]. Moreover, the 
mesenchymal phenotype is another hallmark of tumor aggressiveness in GBM [76 , 77]. 
Remarkably, a single UPR component, IRE1?? ????????? ??? ????????? ?????? ?????? ????????? ???
GBM aggressiveness. Indeed, it was shown that expression of a dominant negative form of 
?????? ?????????? ?? ???????????? ?????? ??? ?????????????? ?????????????? ??? ??????????? ??? ????
expression of extracellular matrix, angiogenesis, and inflammation proteins. This is in 
????????????????????????????? ?????????????????????????????????????????????? ???????[78 , 
79]? ???? ???????? ?????? ??? ???? ?????? ???????? ???????? ???????? ????????? ??? ?east one driver 
mutation [78]??????????????????????????????????????????????????????????????????????????????
????????? ??????? ??? ?? ???????????????? ???????? ??? ????? ??????? ?????-driven modulation of 
angiogenesis was attributed to the positive regulation of pro-angiogenic factors such as 
VEGF-A, IL-??????? ??-6 secretion [80, 81] and the cleavage of the mRNA codding for the 
circadian gene PERIOD1 [82]. Adding to its role in the regulation of angiogenesis, PERIOD1 
????? ?????????? ?????–dependent GBM infiltration [82]?? ???????? ?????? ?????????????????
substrate, the mRNA coding for the extracellular matrix protein SPARC was also found to be 
involved in modulation of GBM invasion ability in an autocrine fashion [83]. Taken together, 
these data underline that IRE1?? ??? ???????? ???? ????? ????? ??????????? ???? ?????????? ???????? ???
control the phenotype, the physiology and the aggressiveness of GBM. 
C.2. UPR in triple negative breast cancer
Triple negative breast cancers (TNBC) represent the most aggressive breast cancer subtype, 
with high rates of tumor recurrence and poor overall survival [84]. Although the lack of 
expression of the estrogen, progesterone and HER2 receptors clusters these tumors within the 
same group, they still comprise heterogeneous and poorly characterized breast cancers with 
no selective therapy [85]. Recently, a study by Chen and colleagues [86] revealed the 
contribution of the UPR to TNBC, in particular through the cross-talk with HIF-1?, a 
transcription factor previously shown to be of particular importance in the hypoxic response 
in TNBC. Chen and colleagues characterize a new molecular mechanism, XBP1s-dependent 
HIF-1?  activation in TNBC, thereby indicating potential novel therapeutic strategies 
mediated through the inhibition of XBP1 in TNBC [87]. These observations could also be 
linked to the acquisition of a mesenchymal phenotype by breast tumor cells. Indeed, increased 
expression of XBP1 is associated with the progression of breast cancer and XBP1s is 
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significantly over-expressed in matched metastatic tumors, which can act as a major regulator 
of EMT through SNAIL signaling [88]. Moreover, as autophagy and UPR signaling also 
appear to be interconnected, combined chloroquine (CQ), a pharmacological inhibitor of 
autophagy, with other drugs known to act as ER stress enhancers (nelfinavir (an HIV protease 
inhibitor) and celecoxib (a cyclooxygenase-2 inhibitor) or its non-coxib analog 2,5-dimethyl-
celecoxib (DMC)) were tested in TNBC. Addition of CQ resulted in synergistic enhancement 
of tumor cell killing by ER stress aggravators in vitro and in vivo, thus opening novel 
therapeutic avenues for TNBC [89]. 
D. Conclusions and future perspectives
Collectively, the afore-mentioned information sheds light on the intricate cancer signaling 
networks into which the UPR is involved. From this analysis it becomes evident that 
characterizing the UPR status in tumors might not only represent a good predictor of the 
disease outcome but also constitute an essential toolkit for better defining personalized 
treatments and following up treatment efficacy. As such, a thorough analysis of the UPR in 
tumors could be envisioned to firstly select the best and most relevant markers/predictors of 
tumor characteristics and then secondly to apply the most efficient targeted therapies to those 
tumors. Needless to say that in this context, therapies targeting the UPR itself could also be of 
interest either alone or as adjuvant therapies. In conclusion, the specificity of UPR signals and 
its impact on tumor phenotype represents an interesting avenue to better characterize 
carcinogenesis but also when documented in patients’ tumors will constitute a novel basis for 
tumor typing and specialized treatments.
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Figures and Legends
Figure 1: Cancer relevant UPR signaling components – Major UPR signaling modules are 
drawn.  Relevance to cancer is indicated as follows: Orange - proteins directly implicated in 
the modulation of cancer cell features, including initiation, angiogenesis, inflammation, 
immunogenicity or resistance. Green - proteins whose modulation or activation is observed in 
cancer tissues or involved with cancer development or aggressiveness, but whose role in the 
control of cancer features is not clearly defined.
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Figure 2: Normal vs. cancer cell secretory pathway control and biological outcomes. In 
normal cells, the secretory pathway adapts to fluctuation of environmental stresses and 
intracellular needs, through a complex molecular signaling pathway: the unfolded protein 
response (UPR). This adaptation program is triggered by three ER transmembrane sensors, 
namely IRE1, PERK and ATF6. The cell secretory proteins needs vary depending on cell 
type, differentiation state or on the physiological context. In cancer cells, the secretory 
pathway is subjected to a strong environmental pressure due to environmental stress factors, 
such as hypoxia, oxidative stress or chemotherapies, and to oncogenic pressure (e.g. 
Myc/aneuploidy stimulation of transcription). Furthermore, in these cells, the increase in 
secretion demand is also dependent on a substantial requirement of energy and amino acid 
supply. The integration of both intrinsic and extrinsic challenges results in disturbance of the 
ER homeostasis causing the UPR to be constitutively active in these cells. Disturbance of the 
secretory pathway will, as a consequence, lead to the modulation of the secretion of proteins 
important for cancer features such as growth factors and their associated receptors, 
extracellular matrix proteins, matrix metalloproteases, inflammatory factors, integrins, 
immunogenic factors or pro angiogenic factors.
